Oncology Models | Charles River Discovery Services

Neurotoxicity Model 

Peripheral neurotoxicity occurs in approximately 40 percent of previously untreated cancer patients who receive taxane-containing chemotherapy regimes. Because the effects of this therapy may limit treatment for a significant percentage of patients, the Charles River model that mimics clinical toxicity is significant. The model permits the evaluation of interactions of proposed protectant strategies for the disease and its treatment.

For more information about our neurotoxicity model, please contact us at askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

+33 (0)4 74 01 69 69
askcharlesriver@crl.com

view all

News & Events

view all
mai 14 - New Models for Evaluating COPD or ...
mai 11 - Expert Safety Testing to Accelerat...
juin 14-juin 14 - Hørsholm, Denmark - Biotech Outsourcing Strategies (chemistry, manufa...
juin 02-juin 05 - Vancouver, British Columbia - CALAS
juin 05-juin 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Bi...
juin 05-juin 08 - Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA, US

Charles River Laboratories, Inc.